Can Dividend Stocks Novo Nordisk and Novartis Continue to Perform?
Dividends and growth -- watch below to learn more about these stocks
3 Things to Look for in MannKind's Partnership
Merck would be a perfect partner for MannKind; Novo Nordisk and Eli Lilly are likely out.
MannKind Stock: Afrezza Approved at Last, But Will Sales Disappoint?
MannKind finally got its approval for inhaled insulin, but the marketing challenges are only beginning.
MannKind's Afrezza Approved but Will Doctors Prescribe It?
MannKind is going to have a hard time competing with Novo Nordisk and Eli Lilly, especially in type 1 diabetics.
Up 9%: What You Need to Know About MannKind Today
MannKind's Afrezza is approved but can it compete with injected insulin from Novo Nordisk and Eli Lilly?